









Markets
/
Stocks
/
nasdaq-cpix
/

Cumberland Pharmaceuticals Inc

CPIX

3.910USD

+0.320+8.91%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

58.48MMarket Cap

LossP/E TTM



Cumberland Pharmaceuticals Inc

3.910

+0.320+8.91%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Cumberland Pharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

Cumberland Pharmaceuticals Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 92 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 0.00.In the medium term, the stock price is expected to trend up.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cumberland Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

92 / 159

Overall Ranking

250 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive+

Cumberland Pharmaceuticals Inc Highlights

StrengthsRisks

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

Growing

The company is in a growing phase, with the latest annual income totaling USD 37.87M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 37.87M.

Undervalued

The company’s latest PE is -16.90, at a low 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 515.47K shares of this stock.

Analyst Rating

Based on 1 analysts

Hold

Current Rating

0.000

Target Price

0.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Cumberland Pharmaceuticals Inc is 7.87, ranking 94 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 8.29M, representing a year-over-year decrease of 8.73%, while its net profit experienced a year-over-year decrease of 25.69%.

Score

Industry at a Glance

Previous score

7.87

Change



Financials

7.58

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.62

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.88

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.29

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Cumberland Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Cumberland Pharmaceuticals Inc is 8.81, ranking 6 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -16.90, which is -91.80% below the recent high of -1.39 and -46.00% above the recent low of -24.68.

Score

Industry at a Glance

Previous score

8.81

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 92/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Cumberland Pharmaceuticals Inc is 6.00, ranking 135 out of 159 in the Pharmaceuticals industry.

Score

Industry at a Glance

Previous score

6.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Hold

Current Rating

0.000

Target Price

0.00%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Cumberland Pharmaceuticals Inc

CPIX

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Cumberland Pharmaceuticals Inc is 7.08, ranking 82 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 4.81 and the support level at 3.27, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.64

Change

0.44

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.160

Neutral

RSI(14)

48.908

Neutral

STOCH(KDJ)(9,3,3)

42.804

Buy

ATR(14)

0.353

High Vlolatility

CCI(14)

-43.680

Neutral

Williams %R

71.970

Sell

TRIX(12,20)

-0.373

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

3.818

Buy

MA10

3.786

Buy

MA20

4.179

Sell

MA50

3.687

Buy

MA100

3.307

Buy

MA200

3.689

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Cumberland Pharmaceuticals Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 28.11%, representing a quarter-over-quarter increase of 0.00%. The largest institutional shareholder is James Simons, holding a total of 515.47K shares, representing 3.45% of shares outstanding, with 2.43% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Kazimi (A J)

5.70M

+0.01%

Millennium Management LLC

598.63K

-22.85%

Ikarian Capital LLC

555.93K

-6.71%

Renaissance Technologies LLC

Star Investors

515.47K

+4.14%

The Vanguard Group, Inc.

Star Investors

411.79K

Krogulski (Kenneth J)

296.54K

+0.65%

Dimensional Fund Advisors, L.P.

280.87K

+11.06%

J. Goldman & Co., L.P.

208.14K

-5.69%

Bridgeway Capital Management, LLC

188.35K

Boothbay Fund Management, LLC

168.13K

-6.71%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cumberland Pharmaceuticals Inc is 2.19, ranking 135 out of 159 in the Pharmaceuticals industry. The company's beta value is -0.52. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.